Trials / Recruiting
RecruitingNCT05557604
Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer
Sbrt±sTad for Unfavorable iNtermediate rIsk/High Risk Prostate caNcer (STUNNIN): A Randomized Phase II Study
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 146 (estimated)
- Sponsor
- Regina Elena Cancer Institute · Academic / Other
- Sex
- Male
- Age
- 18 Years – 90 Years
- Healthy volunteers
- Not accepted
Summary
This is a prospective, open, randomized phase II trial.
Detailed description
Patients will be randomized between SBRT alone (38 Gy in 4 fractions) or SBRT (same schedule) along with short course (6 months) androgen deprivation (STAD). All patients will be treated by intensity modulated radiotherapy. Regarding the combined modality approach, SBRT has to start within 3 months from the first injection of LHRH analogue.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Decapeptyl | STAD androgen deprivation |
Timeline
- Start date
- 2021-02-02
- Primary completion
- 2024-02-02
- Completion
- 2027-02-02
- First posted
- 2022-09-28
- Last updated
- 2022-09-28
Locations
3 sites across 1 country: Italy
Source: ClinicalTrials.gov record NCT05557604. Inclusion in this directory is not an endorsement.